June 14, 2018

New OICR President and Scientific Director comments on breakthrough in breast cancer T-cell immunotherapy

Dr. Laszlo Radvanyi

For the first time, a patient’s late-stage breast cancer has been successfully treated with T-cell immunotherapy. This cutting-edge approach, which is currently in clinical trials in the U.S., modified the patient’s naturally-occurring immune cells to fight her tumours that had spread throughout her body. The patient has been cancer free for the past two years and her remarkable tumour regression represents the potential impact of this new immunotherapeutic approach.

Continue reading – New OICR President and Scientific Director comments on breakthrough in breast cancer T-cell immunotherapy

June 13, 2018

FACIT Appoints Biotech Veteran Dr. David O’Neill as President

Entrepreneur adds US oncology management experience to Ontario commercialization

David o'NeillTORONTO, ON (June 13, 2018) — The Board of Trustees announced the appointment of David O’Neill as the President of FACIT. Dr O’Neill joined FACIT in 2013 as Vice President, Business Development, bringing cancer drug development expertise as well as an extensive business network in pharma and biotech. As Acting President for the last year, he has elevated the profile of the organization and enabled FACIT to continue to deliver critical commercialization financing to innovative start-ups in the growing Ontario market.

Continue reading – FACIT Appoints Biotech Veteran Dr. David O’Neill as President

May 1, 2018

Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi

Dr. Laszlo Radvanyi

Toronto (May 1, 2018) – Mr. Tom Closson, Chair of the Ontario Institute for Cancer Research’s (OICR) Board of Directors, today welcomed to the Institute Dr. Laszlo Radvanyi, OICR’s new President and Scientific Director. Radvanyi was selected after an extensive international search and has extensive oncology-related experience from his time spent in industry, with a particular focus in immuno-oncology. Radvanyi will work with the Ontario cancer research community, and OICR’s commercialization partner FACIT, to see that Ontario’s best innovations are reaching cancer patients as quickly as possible.

Radvanyi joins OICR from EMD Serono (Merck KGaA, Darmstadt Germany), where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology. There he played a central scientific advisory role, facilitating major academic centre alliances and ran EMD Serono’s CAR T-cell program, in partnership with Intrexon. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform, where he was instrumental in rebuilding immuno-oncology research at the company, hiring new world-class scientific staff, as well as pruning and re-orienting the discovery pipeline.

Continue reading – Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi

March 28, 2018

OICR names Dr. Laszlo Radvanyi as new President and Scientific Director

 

A photo of the MaRS Centre with an inset photo of Dr. Laszlo Radvanyi

Following an extensive international search, I am very pleased to announce on behalf of the Board of Directors the appointment of Dr. Laszlo Radvanyi as the new President and Scientific Director of the Ontario Institute for Cancer Research (OICR) effective May 1, 2018. Dr. Radvanyi was born and raised in Toronto and obtained his PhD in Clinical Biochemistry from the University of Toronto in 1996. After obtaining his PhD, he performed post-doctoral work at Harvard University (Joslin Diabetes Center) and then worked for four years at Sanofi Pasteur Canada as a Senior Scientist in the Immunology Platform. Dr. Radvanyi brings a strong oncology research background as well as leadership experience in international pharma and small biotech. We are pleased to welcome him back to Ontario.

Dr. Radvanyi has joined OICR from EMD Serono (Merck KGaA, Darmstadt Germany) where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology playing a central scientific advisory role, facilitating major academic center alliances, and running EMD Serono’s CAR T-cell program in partnership with Intrexon. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform where he was instrumental in rebuilding immuno-oncology research at the company, hiring new world-class scientific staff as well as pruning and re-orienting the discovery pipeline.

Continue reading – OICR names Dr. Laszlo Radvanyi as new President and Scientific Director

November 22, 2017

FACIT Welcomes Kevin Empey, Cynthia Goh and Shana Kelley to the Board of Trustees

FACIT Logo

FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.

TORONTO, ON (November 21, 2017) — FACIT announced the expansion of its Board of Trustees with the appointment of three new members: Mr. Kevin Empey, Dr. Cynthia Goh, and Dr. Shana Kelley. Their collective appointments strengthen FACIT’s leadership team, bringing additional financial, entrepreneurial and biotech industry expertise and networks, as FACIT advances its mandate to help guide and drive breakthrough Ontario oncology innovations.  The new members join existing Trustees Mr. Greg Gubitz and Mr. John Morrison. As part of this transition, Dr. Doug Squires is stepping down from his position of Chairman, FACIT Board of Trustees.

Continue reading – FACIT Welcomes Kevin Empey, Cynthia Goh and Shana Kelley to the Board of Trustees

May 8, 2017

Interview: Mr. Peter Goodhand, President of OICR

Peter Goodhand

OICR is pleased to announce that Mr. Peter Goodhand is OICR’s new President for a one-year term. Goodhand served as Interim President of OICR over the past 10 months, in addition to his role as Executive Director of the Global Alliance for Genomics and Health (GA4GH). We spoke to Goodhand about why he took on the new, expanded job, how it differs from his previous role, what this means for the search for a permanent OICR President and Scientific Director and what he’s planning for the next year at OICR.

Continue reading – Interview: Mr. Peter Goodhand, President of OICR

March 8, 2017

In London, OICR leaders discussed cancer research advancements being made in the city. How can OICR help further translate these breakthroughs to patients?

London, Ontario

Ontario’s wealth of cancer research expertise is not limited to one city or region. Innovations from researchers and clinician-scientists across the province are changing the approach to cancer worldwide. London is one of Ontario’s major cancer research nodes and boasts a particular strength in developing medical imaging technology. The city is home to the Lawson Health Research Institute, Robarts Research Institute and the Centre for Imaging Technology Commercialization. Life science and biotechnology research is the source of $1.5 billion in economic activity for the city annually.

Continue reading – In London, OICR leaders discussed cancer research advancements being made in the city. How can OICR help further translate these breakthroughs to patients?

July 11, 2016

Dr. Lincoln Stein is named an International Society of Computational Biology Fellow

Dr. Lincoln Stein - Receiving ISCB Fellowship

OICR’s Scientific Director (Interim) and Program Director for Informatics and Bio-computing Dr. Lincoln Stein was officially named an International Society of Computational Biology (ISCB) Fellow this past weekend at the Intelligent Systems for Molecular Biology 2016 conference in Orlando, Florida.

Stein and the rest of the class of 13 Fellows from this year join an illustrious group of 56 existing members who have been conferred with this status since the program was inaugurated in 2009.

For more information about Dr. Stein’s Fellowship, please see the announcement of the award from earlier this year.

June 29, 2016

OICR welcomes Dr. Christine Williams

Dr. Christine Williams

This April OICR welcomed Dr. Christine Williams as Deputy Director and Vice-President, Outreach. Williams joins OICR from The Canadian Cancer Society, where she was the Chief Mission Officer, responsible for overall leadership of the organization’s activities in research, policy, advocacy, information and support programs. Prior to that she was the national Vice-President, Research at the Society where she oversaw a cancer research budget of $40 million each year.

Continue reading – OICR welcomes Dr. Christine Williams